Effects Of Amlodipine On Tgf-Beta-Induced Smad2, 4 Expressions In Adriamycin Toxicity Of Rat Mesangial Cells

Yun-Jie Song,Jin Li,Xian-Fei Xie,Hui Wang,Qi-Xiong Li
DOI: https://doi.org/10.1007/s00204-011-0667-4
2011-01-01
Archives of Toxicology
Abstract:Transforming growth factor-beta (TGF-beta) is closely associated with progressive renal fibrosis. A central component of TGF-beta-stimulated mesangial cell fibrogenesis is the TGF-beta family-specific Smad signal transduction pathway. This study investigated the expression of TGF-beta-receptor-activated Smad2, its common partner Smad4, and the phosphorylated Smad2 (p-Smad2) in adriamycin-induced toxicity of cultured rat mesangial cells. This in vitro study showed that amlodipine (10(-9) to 10(-5) mol/l) had no effect on the toxicity of rat mesangial cells induced by adriamycin in the absence of TGF-beta 1. However, amlodipine (10(-7) to 10(-5) mol/l) reduced the toxicity of rat mesangial cells induced by TGF-beta 1 in the absence of adriamycin; moreover, amlodipine (10(-8) to 10(-5) mol/l) significantly reduced adriamycin-induced cytotoxicity when it was given in combination with TGF-beta 1; amlodipine (10(-6), 10(-5) mol/l) had no effect on Smad2 mRNA and protein expression induced by adriamycin + TGF-beta 1, but it (10(-6), 10(-5) mol/l) dramatically inhibited the down-regulation of p-Smad2 protein expression as well as Smad4 mRNA and protein expression induced by adriamycin + TGF-beta 1 in rat mesangial cells. Present study shows that amlodipine exerts a significant inhibition on adriamycin-induced toxicity in rat mesangial cells by affecting the expression of TGF-beta/Smad signaling intermediates p-Smad2 and Smad4.
What problem does this paper attempt to address?